Personalis Inc logo

Personalis Inc(PSNL)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
4-STAR RATING
PASS
LAST CLOSE
$14.27
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for PSNL

11/20/2026: PSNL (4-star) is currently NOT-A-BUY. Pass it for now.

Personalis Inc is a life sciences and cancer genomics company specializing in advanced precision oncology, population sequencing, and minimal residual disease (MRD) testing. Its core business strengths include its ultra-sensitive NeXT Personal platform and growing Medicare coverage, which are driving clinical test volume expansion. The primary investment story centers on its clinical test adoption and its pending acquisition agreement by Tempus AI. Key risks involve ongoing operating losses, cash consumption, and intense competition from larger diagnostics incumbents. The stock suits growth-oriented investors monitoring healthcare transactions, with future developments depending on merger execution milestones and clinical adoption rates.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile operating in the high-growth precision oncology and MRD market, revenue growth has experienced historical lumpiness.
Momentum investorStrong fit while signal remains positiveStock price action has reacted strongly to corporate acquisition developments and quarterly clinical revenue beats.
Value investorWeak fitThe company remains unprofitable with negative earnings and operating cash flows.
Dividend investorWeak fitPersonalis does not pay dividends and reinvests all capital into business operations.
Low-risk investorWeak fitHigh clinical development costs, regulatory dependencies, and market volatility create substantial investment risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock is sensitive to clinical data readouts, earnings results, and transaction updates.
Valuation riskMedium / highValuation is heavily anchored to pending corporate transaction terms rather than near-term profitability.
Competition risk (Guardant Health and Natera market dominance)HighWell-funded competitors possess expansive commercial sales forces and entrenched lab workflows.
Business qualityMediumThe company features advanced proprietary technology but lacks historical financial self-sustainability.
Dividend incomeLow / noneNo dividend payouts are offered or anticipated.
Execution riskHighSuccessful commercial scaling depends on broad clinical adoption, payer coverage expansion, and merger execution.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.55B USD
Price to earnings Ratio -
1Y Target Price 15.17
Price to earnings Ratio -
1Y Target Price 15.17
Volume (30-day avg) 2.5M shares
Beta 2.36
52 Weeks Range 4.96 - 18.89
Updated Date 11/21/2026
52 Weeks Range 4.96 - 18.89
Updated Date 11/21/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.12

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Diagnostics & Research

BUY participation
14.3%
Active BUY / eligible
1 / 7
30-Day BUY Count Change
-4

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit 74.06%
Avg. Invested days 22
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 4.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
PSNL receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
PSNL has moderate overall fundamentals (3 stars), with soft financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, moderate earnings growth (+0.0%) is partially offset by weak cash generation (FCF margin -114.1%), negative revenue growth (-17.7%), weak profitability (net margin -116.7%).

Financial Health Rating

★★★★★
PSNL's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 68.3%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is PSNL's strongest growth driver at +0.0% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while revenue growth (-17.7%, negative) and free-cash-flow growth (-69.9%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 66.9% and approximately 68.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 25.60% supports management-shareholder alignment.

Top 5 Institutional Investors

Merck & Co Inc 12.96%
ARK Investment Management LLC 7.63%
BlackRock Inc 6.53%
Lightspeed Management Co LLC 5.63%
Ameriprise Financial Inc 5.61%

Unit Economics (Per $1K Revenue)

★★★★★
PSNL generates approximately $227 of gross profit, $-1,264 of operating income, and $-1,141 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.03% (Tax Credit)

Quantitative Style Profile

★★★★★
PSNL has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical DiagnosticsCommercial testing services including NeXT Personal MRD assays billed to biopharma, institutions, and Medicare.This is the core focal point for future high-margin commercial growth.
Biopharma Testing ServicesGenomic sequencing and biomarker analysis contracted by pharmaceutical clients for clinical trials.Provides project-based revenue streams that fluctuate based on drug development pipelines.
Population SequencingLarge-scale sequencing services for government and research cohorts like the Million Veteran Program.Offers steady foundational volume but can create year-over-year revenue comparisons lumpiness.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1.47B
Price to Sales(TTM) 19.15
Enterprise Value 1.47B
Price to Sales(TTM) 19.15
Enterprise Value to Revenue 18.21
Enterprise Value to EBITDA -0.03
Shares Outstanding 108.40M
Shares Floating 73.90M
Shares Outstanding 108.40M
Shares Floating 73.90M
Percent Insiders 25.6
Percent Institutions 66.9

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.